scholarly journals Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer

2021 ◽  
Vol 7 (1) ◽  
pp. 31-38
Author(s):  
Jonathan J. Hue ◽  
Katherine Bingmer ◽  
Kavin Sugumar ◽  
Sarah C. Markt ◽  
Luke D. Rothermel ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Benefit ◽  
Metastatic Pancreatic Cancer

Survival benefit with erlotinib-based chemotherapy in unoperable recurrent and/or metastatic pancreatic cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 15622-15622 ◽  
Author(s):  
G. F. Samelis ◽  
A. Tsiakou ◽  
A. Zaganides ◽  
K. Ekmektzoglou
Keyword(s):  
Pancreatic Cancer ◽  
Survival Benefit ◽  
Metastatic Pancreatic Cancer

scholarly journals Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoon Suk Lee ◽  
Jong-chan Lee ◽  
Jae-Hyeong Kim ◽  
Jaihwan Kim ◽  
Jin-Hyeok Hwang
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Metastatic Pancreatic Cancer ◽  
Cochrane Library ◽  
Chemotherapeutic Regimen ◽  
Free Survival ◽  
Ethnic Subgroups

AbstractTreatment outcomes between FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and GNP (gemcitabine with albumin-bound paclitaxel) as first-line chemotherapy regimens for metastatic pancreatic cancer (PC) were assessed according to ethnic groups categorized as Western or Asian subgroups. PubMed, EMBASE, and Cochrane library were searched. Thirteen studies were eligible in this meta-analysis. Overall survival was not significantly different between FOLFIRINOX and GNP (HR 1.00, 95% CI 0.83–1.20, P = 0.990). However, the Western subgroup showed a higher survival benefit for FOLFIRINOX over GNP (HR 0.84, 95% CI 0.74–0.95, P = 0.006) whereas the Asian subgroup showed the survival benefit for GNP over FOLFIRINOX (HR 1.29, 95% CI 1.03–1.60, P = 0.030). Progression free survival was not significantly different between the two regimens in the Western subgroup (HR 1.01, 95% CI 0.84–1.20, P = 0.950) and the Asian subgroup (HR 1.13, 95% CI 0.97–1.33, P = 0.110). Occurrence of febrile neutropenia was significantly higher in FOLFIRINOX at both ethnic subgroups; however, that of peripheral neuropathy was significantly higher only in GNP of the Asian subgroup. Therefore, pharmacoethnicity might be a factor worth considering when deciding on a frontline chemotherapeutic regimen although the overall survival was not significantly different between FOLFIRINOX and GNP for metastatic PCs.

Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients

2011 ◽  
Vol 58 (110-111) ◽  
Author(s):  
Georgios F. Samelis ◽  
Konstantinos Ekmektzoglou ◽  
Andriani Tsiakou ◽  
Styliani Giannakaki ◽  
Manoussos Konstadoulakis
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Survival Benefit ◽  
Metastatic Pancreatic Cancer
Sign in / Sign up

Export Citation Format

Share Document